Follow The Filings

BMY Bristol Myers Squibb

Health Care, filed as BRISTOL-MYERS SQUIBB CO (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 2

  • 1 Owner
  • #102
  • Max 0.4%
  • Master 0.06%
  • $777K
  • 1 add

In 2026 Q3 Kentucky Trust added to Bristol Myers Squibb.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

  1. Kentucky Trust Co. Add 0.39%

Who owns BMY

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust 0.39%, was 0.34% Add +0.6% 12,458 $777K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BMY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BMY insider trades
  • None no insider bought on the open market
  • $437K sold by 2 insiders outside a trading plan
  • $1.9M sold by 1 insider under 10b5-1 plans
  1. Cristian Massacesi EVP,Chief Med Offr,Head of Dev
    Sale
    $403K 6,249 shares at $64.57 25% of stake
    Traded Sep 9 Filed Sep 10
    ↗
  2. Phil M Holzer SVP and Controller
    Sale
    $34K 500 shares at $67.50 2.9% of stake
    Traded Aug 25 Filed Aug 26
    ↗
  3. David V Elkins CFO
    Planned sale
    $1.9M 30,000 shares at $61.67 16% of stake
    Traded Apr 1 Filed Apr 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 49 option exercises, 48 share withholdings for taxes, and 37 other transactions.

Congress

12 members of Congress traded BMY in the last three years: 9 buys and 16 sales. 14 members listed it in 2025 annual reports.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  2. Mike Kelly R-PA-16Spouse Sell $15K–$50K May 7 filed Jun 11
  3. Julie Johnson D-TX-32Joint Sell $1K–$15K Dec 18, 2025 filed Jan 15
  4. Julia Letlow R-LA-5 Sell $1K–$15K Apr 28, 2025 filed Jan 13
  5. Julia Letlow R-LA-5 Buy $1K–$15K Oct 23, 2024 filed Jan 13
  6. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Dec 19, 2025 filed Jan 12

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $45.01B $48.3B $48.19B
Gross profit * $34.31B $34.33B $34.26B
Gross margin * 76.2% 71.1% 71.1%
Net income $8.02B -$8.95B $7.05B
Net margin * 17.8% -18.5% 14.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $31.77B $29.78B $29.39B
Total non-current assets * $63.39B $62.82B $60.65B
Total assets $95.16B $92.6B $90.04B
Total current liabilities $22.26B $23.77B $23.42B
Total non-current liabilities * $43.41B $52.44B $48.12B
Total equity $29.43B $16.34B $18.47B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $13.86B $15.19B $14.16B
Cash from investing -$2.3B -$21.35B -$4.13B
Cash from financing -$9.42B $5.13B -$10.35B
Net change in cash $2.19B -$1.17B -$0.129B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.